語系
| 繁中 | 简中 | EN 
A Multi-Modal Assay for Quantitating and Interpreting Changes in Autophagic Flux
Tuesday, October 23, 2018
Live webcast
9:00am CDT/10:00am EDT/7:00am PDT
3:00pm London/4:00pm Amsterdam-Paris
This webinar is in collaboration with Aurelia Bioscience, UK
Monitoring autophagy using imaging or western blotting methods can be cumbersome, low-throughput and subjective. Learn about a new LC3 reporter assay with three modalities (plate-reader based, imaging and blotting) to help scale up your autophagy analysis with confidence.
Join us live to share your challenges with autophagy assays and test your knowledge of the pathway.
Dan Lazar, PhD
Dr. Dan Lazar received his Ph.D. in biological chemistry from the University of Michigan and then completed a postdoctoral fellowship focused on cell signaling at Warner Lambert/Parke-Davis. Subsequently, he was a Team Leader and Senior Scientist at Eli Lilly within the metabolic disease drug-discovery area for well over a decade where he gained extensive experience in the development, validation and implementation of cell-based and biochemical assays for drug discovery. As a Group Leader and Senior Research Scientist at Promega, Dan and his colleagues are principally focused on delivering novel cell-based assays for the quantitative assessment of various aspects of cell health to assist academic and industrial investigators.
Dan Lazar, PhD
Dr. Gary Allenby has a Ph.D. in reproductive toxicology, and studied the pharmacology of retinoid biology as a post-doc at Hoffmann La Roche, USA. He returned to the UK in 1995 to join the Lead Generation group at Glaxo Wellcome. There he developed cell-based assays for high throughput screening and worked with vendors to validate new technologies for screening and automated HTS. In 2000, he joined the Hit Identification group at AstraZeneca, developing assays for respiratory and inflammatory disease while continuing to work with vendors and automated assays.
In 2011, Dr. Allenby became a founding entrepreneur of Aurelia Bioscience, a pre-clinical contract research organization located in Nottingham, UK. Aurelia Bioscience focuses on developing and implementing innovative cell-based assays for screening, and collaborate with vendors to deliver value-adding data for drug discovery purposes.